Metabolic · COMPOUND PROFILE

Semaglutide

Ozempic · Wegovy · Rybelsus

Semaglutide is a GLP-1 receptor agonist available in multiple prescription products. Ozempic, Wegovy, and Rybelsus are familiar brand names, but they should not be treated as interchangeable instructions. Different formulations and strengths have different labels, approved uses, administration requirements, and patient populations.

Editorial standards · Updated Oct 27, 2026
WHO RESEARCHES THIS?

Who researches Semaglutide?

This profile is for readers exploring metabolic biology and the evidence behind this compound. Topic associations help locate research; they do not establish that a substance is suitable for personal use

Start with the beginner’s guide if the terminology is new, then read the limitations alongside the findings

ACCESS & COSTWhat does Semaglutide cost?Understand product-specific access and official cost resources→

What is Semaglutide?

Semaglutide illustrates why an ingredient guide needs to be more careful than a simple dosing chart. The same active ingredient can appear in products with different presentations, administration requirements, and approved indications. As labeling evolves, an older summary may no longer describe all available options. The most useful comparison begins with the exact product, the condition being treated, and the endpoint measured. This profile explains those distinctions and encourages readers to verify current prescribing information before interpreting a number taken from a trial or advertisement.

Also searched as Ozempic, Wegovy, Rybelsus

Body measurements and weight tracking
Body measurements and weight tracking Photo: Pexels
THE BIOLOGY

How it works

The peptide mimics selected actions of the intestinal hormone GLP-1. Its effects include glucose-dependent insulin secretion, changes in glucagon release, slower gastric emptying, and reduced appetite. Formulation matters because absorption after swallowing a medicine differs from absorption after injection. Milligram numbers therefore cannot be compared casually across presentations or across different drugs.

Laboratory research and scientific methods
Laboratory research and scientific methods Photo: Pexels

Benefits & what the research shows

Randomized studies support specific clinical uses of approved semaglutide products. Assess the endpoint being discussed: HbA1c, body weight, cardiovascular events, or another disease outcome. A result from one indication does not automatically establish every proposed use. Regulatory labeling has evolved, including newer presentations and strengths, so an old dosing chart may be incomplete.

Read the study, not just the headline

Check the species, population, formulation, comparator, and endpoint before applying a result to a different situation

How to read a peptide study ↗
What this evidence cannot tell us

This overview does not rank all current semaglutide presentations or reproduce every indication. Trial averages hide variation in response and discontinuation. Claims that every person will achieve the headline percentage, or that a compound is equivalent because its name resembles semaglutide, go beyond the evidence. Verify the exact product and current label with the prescriber.

Dosage & administration

Follow the current labeling for the exact prescribed presentation. Oral and injectable formulations have different administration instructions; do not substitute schedules or strengths. Dose changes should follow the prescriber’s plan. This page intentionally avoids a universal maximum dose because available products and labeling continue to change.

Laboratory research and scientific methods
Laboratory research and scientific methods Photo: Pexels

Side effects & safety

Gastrointestinal effects are common. Relevant labels include important warnings and contraindications, including medullary thyroid carcinoma or MEN2 history. Discuss other glucose-lowering medicines, pregnancy plans, severe gastrointestinal disease, dehydration, and relevant eye disease with a clinician. Storage and administration errors can create additional risks independent of the pharmacology.

A healthcare consultation
A healthcare consultation Photo: Pexels

Semaglutide vs related compounds

Compare the research questions and mechanisms. These summaries do not establish equivalent benefits or interchangeable products

CompoundResearch context
SemaglutideThe peptide mimics selected actions of the intestinal hormone GLP-1.
AOD-9604The development rationale focused on separating proposed lipid-related effects from other growth hormone actions.
CagrilintideAmylin participates in the regulation of satiation and food intake.
Open the full comparison ↗

Sourcing & quality

FDA-approved semaglutide medicines are available in the United States. FDA has separately warned about unapproved versions and salt forms. Compounded products are not FDA approved, and a research-use label is not evidence of treatment quality.

Regulatory details can change. Verify the current, product-specific record before making a clinical or purchasing decision

Understand FDA approval and research use
RESEARCH IN FOCUS

Inside the research

Photographs of clinical and laboratory settings, alongside the questions researchers investigate

Laboratory research and scientific methodsSemaglutide

The research setting

The peptide mimics selected actions of the intestinal hormone GLP-1.

Laboratory research and scientific methodsSemaglutide

How the research is investigated

Randomized studies support specific clinical uses of approved semaglutide products.

Frequently asked questions

Why does the exact semaglutide product matter?

Formulation, strength, route, and labeled use can differ. An instruction for one presentation is not a universal instruction for every semaglutide medicine.

What is the United States regulatory context for Semaglutide?

FDA-approved semaglutide medicines are available in the United States. FDA has separately warned about unapproved versions and salt forms. Compounded products are not FDA approved, and a research-use label is not evidence of treatment quality.

Sources & further reading

Official records and research discovery links. A database search is a starting point for finding studies, not a citation to a specific clinical result

  1. FDA: higher-dose Wegovy approval ↗
  2. FDA: unapproved GLP-1 products ↗
  3. PubMed discovery search: Semaglutide (search results, not a clinical endorsement) ↗
AI-generated portrait of Elena Morris
ABOUT THIS CONTRIBUTOR

Elena Morris

Fictional editorial character used for this site demonstration. No medical credentials or independent clinical review are claimed

Read the full profile and disclosure ↗